XML 26 R13.htm IDEA: XBRL DOCUMENT v3.26.1
REVENUE RECOGNITION
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION

NOTE 5 – REVENUE RECOGNITION

 

The Company’s sole source of revenue is product revenue from the sale of pharmaceutical products through wholesale distribution channels. ARBLI™ (SCN-102, Losartan Potassium Oral Suspension) received FDA approval in March 2025 and commenced commercialization in the third quarter of 2025. Revenue is recognized when control transfers to the wholesale distributor, generally upon delivery.

 

Revenue is measured at the net transaction price equal to the gross invoice price reduced by estimated variable consideration. Gross-to-net adjustments include:

 

Chargebacks. The difference between the invoice price charged to wholesale distributors and the lower contract price distributors extend to end-customers (retail pharmacies, hospitals, clinics). Estimated based on expected sell-through and contractual terms.

 

Wholesaler Rebates and Distribution Service Fees. Fees and rebates paid to wholesale distributors and group purchasing organizations under contractual arrangements. Estimated based on contracted rates and expected sales volumes.

 

Prompt Pay Discounts. Discounts offered to wholesale distributors for timely payment, estimated based on contractual terms.

 

Product Returns. Returns accepted under limited conditions (generally damaged, expired, or defective product). Returns have not been material to date given the early stage of ARBLI™ commercialization.

 

Estimates of variable consideration are reassessed each reporting period. Changes in estimates are recorded as adjustments to revenue in the period identified. Accrued gross-to-net liabilities are included within accrued liabilities on the consolidated balance sheets.

 

Revenue disaggregated by product for the three months ended March 31, 2026 and 2025 is as follows:

 

Product  2026   2025 
   Three Months Ended 
   March 31, 
Product  2026   2025 
ARBLI™ (SCN-102, Losartan Potassium Oral Suspension)  $56,325   $- 

Pharmaceutical product resale

   -    10,258 
Total revenues  $56,325   $10,258